Australia markets closed

Merck KGaA (0O14.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
159.15-0.55 (-0.34%)
At close: 05:59PM GMT
Full screen
Previous close159.70
Bid157.50 x 0
Ask160.80 x 0
Day's range157.89 - 184.08
52-week range135.15 - 202.30
Avg. volume189,929
Market cap73.617B
Beta (5Y monthly)0.65
PE ratio (TTM)22.48
EPS (TTM)7.08
Earnings dateN/A
Forward dividend & yield2.20 (1.48%)
Ex-dividend date02 May 2023
1y target estN/A
  • Simply Wall St.

    Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 85% Above Its Share Price

    Key Insights The projected fair value for Merck KGaA is €297 based on 2 Stage Free Cash Flow to Equity Current share...

  • Thomson Reuters StreetEvents

    Q3 2023 Exscientia PLC Earnings Call

    Q3 2023 Exscientia PLC Earnings Call

  • Reuters

    Merck KGaA says FY profit to fall to lower half of target range

    FRANKFURT (Reuters) -Germany's diversified group Merck KGaA flagged that full-year operating earnings would likely be in the lower half of its target range on weak demand for specialty materials that are used to make biotech drugs and semiconductors. The maker of pharmaceuticals, lab gear and specialty chemicals confirmed that 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, would come in between 5.8 billion euros ($6.21 billion) and 6.4 billion euros but would be "trending in the lower half of the absolute range". Last month, Merck raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.